GlassScriptPhysician profile
Margaret Florczyk
NPI 1013927755
$573.32
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $16.41 · 2021: $147 · 2022: $25.72.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $102.42 | 2019-2022 | |
| Incyte Corporation | $99.99 | 2021 | |
| Amgen INC. | $72.68 | 2019-2021 | |
| Pfizer INC. | $68.54 | 2019 | |
| Janssen Biotech, INC. | $48.79 | 2019 | |
| Genentech USA, INC. | $42.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.98 | 2019 | |
| Merck Sharp & Dohme LLC | $27.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.08 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.75 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.20 | 2022 | |
| Celgene Corporation | $12.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Florczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.